Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
PLoS One ; 13(4): e0196017, 2018.
Article in English | MEDLINE | ID: mdl-29672570

ABSTRACT

While measurement of serum prostate specific antigen (PSA) is an important screening tool for prostate cancer, new biomarkers are necessary for better discrimination between presence and absence of disease. The MIL-38 monoclonal antibody is specific for the membrane glycoprotein glypican 1 (GPC-1) and binds to prostate cancer tissue. Urine is known to be a source of cellular material. Thus, we hypothesized that detection of GPC-1 in urine cellular material may identify individuals with prostate cancer. Urine samples from patients with prostate cancer, benign prostatic hyperplasia (BPH), or normal controls were collected and cell sediments prepared. GPC-1-positive cells were detected using a MIL-38 immunofluorescence assay (IFA) and samples were classed positive or negative for GPC-1 expressing cells. Assay sensitivity and specificity, stratified by PSA, was reported. A total of 125 patient samples were analyzed (N = 41 prostate cancer; N = 37 BPH; N = 47 normal controls). The use of MIL-38 to detect GPC-1 by IFA discriminated between prostate cancer and BPH urine specimens with a sensitivity and specificity of 71% and 76%, respectively. Assay specificity increased with increasing PSA, with the highest specificity (89%) for patients with PSA ≥4 ng/ml. At lower PSA (<2 ng/ml) specificity decreased, as evidenced by a greater number of false positives in this concentration range. The odds ratio (OR) and 95% confidence intervals (CIs) for GPC-1-positive cells in patients with prostate cancer, adjusted for PSA, was greatest at the lowest serum PSA (<2 ng/ml; OR = 13.4; 95% CI: 4.0-44.7) compared with no adjustment for PSA (OR = 6.4; 95% CI: 2.8-14.9). The use of MIL-38 for detection of GPC-1 may be a useful tool for detection of prostate cancer.


Subject(s)
Glypicans/urine , Prostatic Neoplasms/urine , Aged , Biomarkers, Tumor , Case-Control Studies , Glypicans/genetics , Humans , Male , Middle Aged , Neoplasm Grading , Odds Ratio , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/genetics , Sensitivity and Specificity , Urinalysis
2.
Anal Biochem ; 496: 30-4, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26717899

ABSTRACT

The mass spectrometry technique of multiple reaction monitoring (MRM) was used to quantify and compare the expression level of lactoferrin in tear films among control, prostate cancer (CaP), and benign prostate hyperplasia (BPH) groups. Tear samples from 14 men with CaP, 15 men with BPH, and 14 controls were analyzed in the study. Collected tears (2 µl) of each sample were digested with trypsin overnight at 37 °C without any pretreatment, and tear lactoferrin was quantified using a lactoferrin-specific peptide, VPSHAVVAR, both using natural/light and isotopic-labeled/heavy peptides with MRM. The average tear lactoferrin concentration was 1.01 ± 0.07 µg/µl in control samples, 0.96 ± 0.07 µg/µl in the BPH group, and 0.98 ± 0.07 µg/µl in the CaP group. Our study is the first to quantify tear proteins using a total of 43 individual (non-pooled) tear samples and showed that direct digestion of tear samples is suitable for MRM studies. The calculated average lactoferrin concentration in the control group matched that in the published range of human tear lactoferrin concentration measured by enzyme-linked immunosorbent assay (ELISA). Moreover, the lactoferrin was stably expressed across all of the samples, with no significant differences being observed among the control, BPH, and CaP groups.


Subject(s)
Lactoferrin/analysis , Tears/chemistry , Aged , Aged, 80 and over , Amino Acid Sequence , Calibration , Case-Control Studies , Humans , Isotope Labeling , Lactoferrin/chemistry , Limit of Detection , Male , Middle Aged , Prostatic Hyperplasia/metabolism , Reproducibility of Results
3.
Crit Rev Oncol Hematol ; 96(3): 507-17, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26253360

ABSTRACT

The phosphatidylinositol-3-kinase/Akt and the mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is one of the most frequently activated signaling pathways in prostate cancer (CaP) and other cancers, and responsible for the survival, metastasis and therapeutic resistance. Recent advances in radiation therapy indicate that activation of this pathway is closely associated with cancer radioresistance, which is a major challenge for the current CaP radiation treatment. Therefore, targeting this pathway by inhibitors to enhance radiosensitivity has great potential for clinical benefits of CaP patients. In this review, we summarize the recent findings in the PI3K/Akt/mTOR pathway in CaP radiotherapy research and discuss the potential use of the PI3K/Akt/mTOR pathway inhibitors as radiosensitizers in the treatment of CaP radioresistance in preclinical studies to explore novel approaches for future clinical trials.


Subject(s)
Phosphoinositide-3 Kinase Inhibitors , Prostatic Neoplasms/drug therapy , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Radiation Tolerance/drug effects , Radiation-Sensitizing Agents/therapeutic use , TOR Serine-Threonine Kinases/antagonists & inhibitors , Humans , Male , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Signal Transduction/drug effects
4.
Prostate ; 74(6): 602-17, 2014 May.
Article in English | MEDLINE | ID: mdl-24615685

ABSTRACT

INTRODUCTION: Prostate cancer (CaP) is the second leading malignancy in older men in Western countries. The role of CD44 variant 6 (CD44v6) in CaP progression and therapeutic resistance is still uncertain. Here, we investigated the roles of CD44v6 in CaP metastasis and chemo/radioresistance. Expression of CD44v6 in metastatic CaP cell lines, human primary CaP tissues and lymph node metastases was assessed using immunofluorescence and immunohistochemistry, respectively. METHODS: Knock down (KD) of CD44v6 was performed in PC-3M, DU145, and LNCaP cells using small interfering RNA (siRNA), and confirmed by confocal microscope, Western blot and quantitative real time polymerase chain reaction (qRT-PCR). Cell growth was evaluated by proliferation and colony formation assays. The adhesive ability and invasive potential were assessed using a hyaluronic acid (HA) adhesion and a matrigel chamber assay, respectively. Tumorigenesis potential and chemo-/radiosensitivity were measured by a sphere formation assay and a colony assay, respectively. RESULTS: Over-expression of CD44v6 was found in primary CaP tissues and lymph node metastases including cancer cells and surrounding stromal cells. KD of CD44v6 suppressed CaP proliferative, invasive and adhesive abilities, reduced sphere formation, enhanced chemo-/radiosensitivity, and down-regulated epithelial-mesenchymal transition (EMT), PI3K/Akt/mTOR, and Wnt/ß-catenin signaling pathway proteins in vitro. CONCLUSIONS: Our findings demonstrate that CD44v6 is an important cancer stem cell-like marker associated with CaP proliferation, invasion, adhesion, metastasis, chemo-/radioresistance, and the induction of EMT as well as the activation PI3K/Akt/mTOR and Wnt signaling pathways, suggesting that CD44v6 is a novel therapeutic target to sensitize CaP cells to chemo/radiotherapy.


Subject(s)
Hyaluronan Receptors/metabolism , Lymphatic Metastasis/genetics , Prostatic Neoplasms/metabolism , Cell Line, Tumor , Cell Proliferation , Humans , Hyaluronan Receptors/genetics , Lymphatic Metastasis/pathology , Male , Phosphorylation , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-akt/metabolism
5.
Cancer Metastasis Rev ; 33(2-3): 469-96, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24445654

ABSTRACT

Radiation therapy (RT) continues to be one of the most popular treatment options for localized prostate cancer (CaP). Local CaP recurrence after RT is a pattern of treatment failure attributable to radioresistance of cancer cells. One major obstacle to RT is that there is a limit to the amount of radiation that can be safely delivered to the target organ. Recent results indicate that phosphoinositide 3-kinase (PI3K)/Akt/phosphatase and tensin homolog (PTEN)/mammalian target of rapamycin (mTOR) signaling pathway, autophagy, epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are involved in CaP metastasis and radioresistance. Emerging evidence also suggests that combining a radiosensitizer with RT increases the efficacy of CaP treatment. Understanding the mechanisms of radioresistance will help to overcome recurrence after RT in CaP patients and prevent metastasis. In this review, we discuss the novel findings of PI3K/Akt/PTEN/mTOR signaling pathway, autophagy, EMT and CSCs in the regulation of CaP metastasis and radioresistance, and focus on combination of radiosensitizers with RT in the treatment of CaP in preclinical studies to explore novel approaches for future clinical trials.


Subject(s)
Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Radiation Tolerance , Animals , Autophagy , Combined Modality Therapy , Epithelial-Mesenchymal Transition , Humans , Male , Neoplasm Metastasis , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/radiation effects , PTEN Phosphohydrolase/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/therapy , Proto-Oncogene Proteins c-akt/metabolism , Radiation-Sensitizing Agents/pharmacology , Radiation-Sensitizing Agents/therapeutic use , Signal Transduction , TOR Serine-Threonine Kinases/metabolism
6.
PLoS One ; 7(8): e40716, 2012.
Article in English | MEDLINE | ID: mdl-22870202

ABSTRACT

CD44 and CD147 are associated with cancer metastasis and progression. Our purpose in the study was to investigate the effects of down-regulation of CD44 or CD147 on the metastatic ability of prostate cancer (CaP) cells, their docetaxel (DTX) responsiveness and potential mechanisms involved in vitro and in vivo. CD44 and CD147 were knocked down (KD) in PC-3M-luc CaP cells using short hairpin RNA (shRNA). Expression of CD44, CD147, MRP2 (multi-drug resistance protein-2) and MCT4 (monocarboxylate tranporter-4) was evaluated using immunofluorescence and Western blotting. The DTX dose-response and proliferation was measured by MTT and colony assays, respectively. The invasive potential was assessed using a matrigel chamber assay. Signal transduction proteins in PI3K/Akt and MAPK/Erk pathways were assessed by Western blotting. An in vivo subcutaneous (s.c.) xenograft model was established to assess CaP tumorigenecity, lymph node metastases and DTX response. Our results indicated that KD of CD44 or CD147 decreased MCT4 and MRP2 expression, reduced CaP proliferation and invasive potential and enhanced DTX sensitivity; and KD of CD44 or CD147 down-regulated p-Akt and p-Erk, the main signal modulators associated with cell growth and survival. In vivo, CD44 or CD147-KD PC-3M-luc xenografts displayed suppressed tumor growth with increased DTX responsiveness compared to control xenografts. Both CD44 and CD147 enhance metastatic capacity and chemoresistance of CaP cells, potentially mediated by activation of the PI3K and MAPK pathways. Selective targeting of CD44/CD147 alone or combined with DTX may limit CaP metastasis and increase chemosensitivity, with promise for future CaP treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Basigin/biosynthesis , Drug Resistance, Neoplasm/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Hyaluronan Receptors/biosynthesis , Neoplasm Proteins/metabolism , Prostatic Neoplasms/metabolism , Taxoids/pharmacology , Animals , Basigin/genetics , Cell Line, Tumor , Cell Proliferation/drug effects , Docetaxel , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm/genetics , Gene Expression Regulation, Neoplastic/genetics , Humans , Hyaluronan Receptors/genetics , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/genetics , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Monocarboxylic Acid Transporters/genetics , Monocarboxylic Acid Transporters/metabolism , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/biosynthesis , Multidrug Resistance-Associated Proteins/genetics , Muscle Proteins/genetics , Muscle Proteins/metabolism , Neoplasm Metastasis , Neoplasm Proteins/genetics , Neoplasm Transplantation , Phosphatidylinositol 3-Kinases/genetics , Phosphatidylinositol 3-Kinases/metabolism , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics , Prostatic Neoplasms/mortality , Transplantation, Heterologous , Xenograft Model Antitumor Assays
7.
Cancer Metastasis Rev ; 31(3-4): 779-91, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22718399

ABSTRACT

Despite significant advances in surgery, radiotherapy and chemotherapy to treat prostate cancer (CaP), many patients die of secondary disease (metastases). Current therapeutic approaches are limited, and there is no cure for metastatic castration-resistant prostate cancer (CRPC). Epithelial cell adhesion molecule (EpCAM, also known as CD326) is a transmembrane glycoprotein that is highly expressed in rapidly proliferating carcinomas and plays an important role in the prevention of cell-cell adhesion, cell signalling, migration, proliferation and differentiation. Stably and highly expressed EpCAM has been found in primary CaP tissues, effusions and CaP metastases, making it an ideal candidate of tumour-associated antigen to detect metastasis of CaP cells in the circulation as well as a promising therapeutic target to control metastatic CRPC disease. In this review, we discuss the implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP. We also summarize EpCAM expression in human CaP and EpCAM-mediated signalling pathways in cancer metastasis. Finally, emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications of EpCAM for targeted strategies in future CaP therapy will be explored.


Subject(s)
Antigens, Neoplasm/physiology , Cell Adhesion Molecules/physiology , Prostatic Neoplasms/pathology , Animals , Antigens, Neoplasm/analysis , Antigens, Neoplasm/chemistry , Biomarkers, Tumor/analysis , Cell Adhesion , Cell Adhesion Molecules/analysis , Cell Adhesion Molecules/antagonists & inhibitors , Cell Adhesion Molecules/chemistry , Disease Progression , Epithelial Cell Adhesion Molecule , Humans , Male , Neoplasm Metastasis , Neoplastic Cells, Circulating , Prostatic Neoplasms/drug therapy
8.
Electrophoresis ; 31(11): 1853-61, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20506419

ABSTRACT

This is the first 2-DE study using sequential dyes to analyse phospho-, glyco- and total tear protein profiles (Pro-Q Diamond for phosphoprotein, Pro-Q Emerald for glycoprotein and Sypro Ruby for total protein). This method minimised the gel-gel variations, allowing better comparisons among the three profiles and generated a whole map of PTM profiles of tear protein. A novel tear protein, dermcidin, was identified for the first time in this study. The identification of this antimicrobial protein suggests a new model of defence in tears. In addition, we are able to present the first experimental evidence of the presence of glycosylated lipocalin 1 and cystatin S. Nucleobindin 2 was only detected using phospho staining, suggesting it is only phosphorylated in tears. This study provides the groundwork for understanding the PTM of tear proteins and consequently these methods could be useful in the search for biomarkers in tears.


Subject(s)
Eye Proteins/metabolism , Protein Processing, Post-Translational , Tandem Mass Spectrometry/methods , Tears/metabolism , Aged , Aged, 80 and over , Electrophoresis, Gel, Two-Dimensional , Eye Proteins/analysis , Glycoproteins/analysis , Glycoproteins/metabolism , Humans , Male , Middle Aged , Peptides/analysis , Peptides/metabolism , Phosphorylation , Reproducibility of Results , Tears/chemistry
9.
Med Res Rev ; 30(1): 67-101, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19536865

ABSTRACT

Prostate cancer (CaP) is one of the most prevalent malignant diseases among men in Western countries. There is currently no cure for metastatic castrate-resistant CaP, and median survival for these patients is about 18 months; the high mortality rate seen is associated with widespread metastases. Progression of CaP from primary to metastatic disease is associated with several molecular and genetic changes that can affect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Targeting TAAs is emerging as an area of promise for controlling late-stage and recurrent CaP. Several reviews have summarized the progress made in targeting signaling pathways for CaP but will not be discussed here. We describe some important CaP TAAs. These include prostate stem-cell antigen, prostate-specific membrane antigen, MUC1, epidermal growth factor receptor, platelet-derived growth factor and its receptor, urokinase plasminogen activator and its receptor, and extracellular matrix metalloproteinase inducer. We summarize recent advancements in our understanding of their role in CaP metastasis, as well as potential therapeutic options for targeting CaP TAAs. We also discuss the origin, identification, and characterization of prostate cancer stem cells (CSCs) and the potential benefits of targeting prostate CSCs to overcome chemoresistance and CaP recurrence.


Subject(s)
Antigens, Neoplasm/blood , Prostatic Neoplasms/therapy , Humans , Male , Neoplasm Metastasis , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology
10.
Med Res Rev ; 30(1): 23-66, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19536866

ABSTRACT

It is becoming increasingly clear that angiogenesis plays a crucial role in prostate cancer (CaP) survival, progression, and metastasis. Tumor angiogenesis is a hallmark of advanced cancers and an attractive treatment target in multiple solid tumors. By understanding the molecular basis of resistance to androgen withdrawal and chemotherapy in CaP, the rational design of targeted therapeutics is possible. This review summarizes the recent advancements that have improved our understanding of the role of angiogenesis in CaP metastasis and the potential therapeutic efficacy of inhibiting angiogenesis in this disease. Current therapeutic options for patients with metastatic hormone-refractory CaP are very limited. Targeting vasculature is a developing area, which shows promise for the control of late stage and recurrent CaP disease and for overcoming drug resistance. We discuss angiogenesis and its postulated mechanisms and focus on the regulation of angiogenesis in CaP progression and the therapeutic beneficial effects associated with targeting of the CaP vasculature to overcome the resistance to current treatments and CaP recurrence.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Neovascularization, Pathologic/drug therapy , Prostatic Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use , Humans , Male , Neoplasm Metastasis , Prostatic Neoplasms/blood supply , Prostatic Neoplasms/pathology
11.
Clin Cancer Res ; 15(3): 865-75, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19188157

ABSTRACT

PURPOSE: To investigate the therapeutic potential of 213Bilabeled multiple targeted alpha-radioimmunoconjugates for treating prostate cancer (CaP) micrometastases in mouse models. EXPERIMENTAL DESIGN: PC-3 CaP cells were implanted s.c., in the prostate, and intratibially in NODSCID mice. The expression of multiple tumor-associated antigens on tumor xenografts and micrometastases was detected by immunohistochemistry. Targeting vectors were two monoclonal antibodies, and a plasminogen activator inhibitor type 2 that binds to cell surface urokinase plasminogen activator, labeled with 213Bi using standard methodology. In vivo efficacy of multiple alpha conjugates (MTAT) at different activities was evaluated in these mouse models. Tumor growth was monitored during observations and local regional lymph node metastases were assessed at the end of experiments. RESULTS: The take rate of PC-3 cells was 100% for each route of injection. The tumor-associated antigens (MUC1, urokinase plasminogen activator, and BLCA-38) were heterogeneously expressed on primary tumors and metastatic cancer clusters at transit. A single i.p. injection of MTAT (test) at high and low doses caused regression of the growth of primary tumors and prevented local lymph node metastases in a concentration-dependent fashion; it also caused cancer cells to undergo necrosis and apoptosis. CONCLUSIONS: Our results suggest that MTAT can impede primary PC-3 CaP growth at three different sites in vivo through induction of apoptosis, and can prevent the spread of cancer cells and target lymph node micrometastases in a concentration-dependent manner. MTAT, by targeting multiple antigens, can overcome heterogeneous antigen expression to kill small CaP cell clusters, thus providing a potent therapy for micrometastases.


Subject(s)
Bismuth , Immunoconjugates/therapeutic use , Prostatic Neoplasms/therapy , Animals , Antibodies, Monoclonal/therapeutic use , Cell Line, Tumor , Disease Models, Animal , Humans , Male , Mice , Mice, Nude , Mice, SCID , Neoplasm Metastasis/prevention & control , Neoplasm Transplantation , Prostatic Neoplasms/pathology , Radioisotopes/therapeutic use , Urokinase-Type Plasminogen Activator/antagonists & inhibitors
12.
Cancer Immunol Immunother ; 57(9): 1367-79, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18273614

ABSTRACT

Extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) is a multifunctional membrane glycoprotein overexpressed in many solid tumors, and involved in tumor invasion and angiogenesis. We investigated EMMPRIN expression in human prostate cancer (CaP) tissues and cells, and evaluated whether EMMPRIN expression is related to tumor progression and matrix metalloproteinase (MMPs) expression in human CaP. An immunohistochemical study using tissue microarrays of 120 primary CaPs of different grades and 20 matched lymph node metastases from untreated patients was performed. The association of EMMPRIN expression with clinicopathological parameters was evaluated. Co-immunolocalization for EMMPRIN and MMP-1, MMP-2 or MMP-9 in primary tumors was examined using confocal microscopy. Flow cytometry and immunoblotting were used to examine EMMPRIN expression in 11 metastatic CaP cell lines. Heterogeneous expression of EMMPRIN was found in 78/120 (65%) CaPs, correlated significantly with progression parameters including pre-treatment PSA level (P < 0.05) and increased with progression of CaP (Gleason score, P < 0.05; pathological stage, P < 0.01; nodal involvement, P < 0.05 and surgical margin, P < 0.05). Heterogeneous cytoplasmic MMP-1, MMP-2 and MMP-9 associated with EMMPRIN immunolabeling was observed, particularly in tumors with Gleason scores >3 + 4. Metastatic CaP cell lines, except DuCaP, expressed abundant EMMPRIN protein, indicating highly ( approximately 45 to approximately 65 kDa) and less ( approximately 30 kDa) glycosylated forms, although with no relationship to cells being either androgen responsive or nonresponsive. Our results suggest that EMMPRIN may regulate MMPs and be involved in CaP progression, and as such, could provide a target for treating metastatic CaP disease.


Subject(s)
Basigin/biosynthesis , Extracellular Matrix/enzymology , Gene Expression Regulation, Neoplastic , Metalloproteases/physiology , Prostatic Neoplasms/enzymology , Antigens, Neoplasm/chemistry , Cell Line, Tumor , Disease Progression , Glycosylation , Humans , Immunohistochemistry/methods , Male , Neoplasm Metastasis , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/pathology , Stromal Cells/metabolism
13.
Hum Pathol ; 37(11): 1442-51, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16949925

ABSTRACT

Increased expression of urokinase plasminogen activator (uPA) and its receptor (uPAR) has been reported in various malignancies including prostate cancer (CaP). However, their expression in the different grades of CaP remains poorly understood. Here, we use tissue microarrays to examine the expression of uPA and uPAR in different grades of human CaP and to establish the potential of these tumor-associated antigens as candidates for targeted therapy. One hundred twenty paraffin-embedded specimens were selected from patients who underwent radical retropubic prostatectomy or transurethral resection of the prostate for primary untreated CaP and 10 matched lymph node metastases. Monoclonal antibodies #394 and #3936 were used on tissue microarrays with standard immunohistochemistry to examine uPA and uPAR expression, respectively. Overexpression of uPA and uPAR was detected in 53% and 64% of primary CaP tissues, respectively, and in more than 90% of lymph node metastases, but not in normal prostates or benign tissues. Of the uPA and uPAR positive tumors, 76% and 68% were Gleason score 7 or higher, respectively, and most of these tumors also showed stromal staining. The overexpression of uPA and uPAR was highly related to tumor differentiation in patients with CaP. Both uPA and uPAR proteins are candidate therapeutic targets for cancer therapy to control micrometastases and hormone refractory disease in CaP.


Subject(s)
Prostatic Neoplasms/pathology , Receptors, Cell Surface/analysis , Urokinase-Type Plasminogen Activator/analysis , Adult , Aged , Gene Expression , Humans , Lymphatic Metastasis , Male , Microarray Analysis , Middle Aged , Prostate/chemistry , Prostate/metabolism , Prostatic Hyperplasia/metabolism , Prostatic Neoplasms/chemistry , Receptors, Urokinase Plasminogen Activator
14.
Prostate ; 66(16): 1753-67, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-16955401

ABSTRACT

BACKGROUND: Micrometastasis is a major problem for prostate cancer (CaP) patients. Our study investigated the therapeutic potential of multiple targeted alpha-therapy (MTAT) in the treatment of CaP micrometastases (spheroids) using (213)Bi-labeled multiple targeted alpha-radioimmunoconjugates. METHODS: The expression of multiple tumor-associated antigens (TAAs) on frozen sections of human fresh CaP tissues and spheroids cultured from DU 145 and LNCaP-LN3 CaP cell lines was detected by immunohistochemistry and flow cytometry. Targeting vectors were two monoclonal antibodies (MAbs), and plasminogen activator inhibitor type 2 (PAI2) that binds to cell surface urokinase plasminogen activator (uPA). These vectors were labeled with (213)Bi using standard methodology. DU 145 and LNCaP-LN3 spheroids were incubated with different activities of test and control alpha-conjugates (ACs), and spheroid growth was measured for volume change and growth delay over a 50-day period using light microscopy. RESULTS: TAAs were expressed heterogeneously on frozen sections from human CaP tissues and CaP spheroids. MTAT combining three ACs (one-third dose of each) with an activity of 6.4 MBq/ml completely targeted small DU 145 and LNCaP-LN3 spheroids (diameter <100 microm) and slightly regressed the growth of medium spheroids (180-200 microm); MTAT with 2.2 or 4.8 MBq/ml activities delayed the growth of tumor spheroids. CONCLUSIONS: Our results suggest that the cytotoxicity of MTAT to CaP spheroids is highly dependent on antigenic expression, concentration of radioactivity and spheroid size. MTAT may be a potent therapeutic agent for micrometastases, effectively targeting small CaP cell clusters, and overcoming the heterogeneous expression of targeted antigens.


Subject(s)
Alpha Particles/therapeutic use , Antibodies, Monoclonal/administration & dosage , Bismuth/administration & dosage , Immunoconjugates/administration & dosage , Prostatic Neoplasms/radiotherapy , Antibodies, Monoclonal/immunology , Antigens, Neoplasm/biosynthesis , Antigens, Neoplasm/immunology , Cell Line, Tumor , Flow Cytometry , Humans , Immunoconjugates/immunology , Immunohistochemistry , Male , Neoplasm Metastasis , Prostatic Neoplasms/immunology , Prostatic Neoplasms/pathology , Spheroids, Cellular
15.
Clin Exp Metastasis ; 22(7): 565-73, 2005.
Article in English | MEDLINE | ID: mdl-16475027

ABSTRACT

Molecular changes are vital for the development of prognostic markers and therapeutic modalities of prostate cancer (CaP). There is growing interest in mucins as treatment targets in human malignancies, including CaP. The role of their expression in the progression of CaP is however unclear. We examined the expressions MUC1, MUC2, MUC4, MUC5AC and MUC6 in CaP tissues using tissue microarrays (TMAs) to look for tumor-associated antigens (TAAs) for targeted therapy. In this study, 120 paraffin-embedded specimens were selected from patients who underwent radical retro-pubic prostatectomy (RRP) or trans-urethral-resection of the prostate (TURP) for primary, untreated CaP and 10 matched lymph node metastases. A series of MUC monoclonal antibodies (mAbs) was used on TMAs by standard immunohistochemistry. Our results indicate that the over-expression of MUC1 was detected in 58% of primary CaP tissues and 90% of lymph node metastases but not in normal prostate or benign tissues, while the expression of MUC2, MUC4, MUC5AC and MUC6 was found to be negative in both normal and cancer tissues. Of the MUC1 positive tumors 86% were Gleason grade 7 or higher. Over-expression of MUC1 was found in late stage CaP while MUC2, 4, 5AC and 6 were negative in CaP. MUC1 is a TAA that is highly related to tumor progression in CaP patients. This antigen is ideal for targeted therapy to control micrometastases and hormone refractory disease but additional studies are necessary to assess its usefulness in patient biopsies and CaP bone metastases before clinical trial.


Subject(s)
Gene Expression Regulation, Neoplastic , Mucins/metabolism , Prostatic Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm , Disease Progression , Humans , Immunohistochemistry , Lymphatic Metastasis , Male , Middle Aged , Mucin 5AC , Mucin-1 , Mucin-2 , Mucin-4 , Mucin-6 , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery
16.
Int J Radiat Oncol Biol Phys ; 60(3): 896-908, 2004 Nov 01.
Article in English | MEDLINE | ID: mdl-15465208

ABSTRACT

PURPOSE: Control of metastatic prostate cancer (CaP) is an elusive objective. Some 30% of patients with clinically localized CaP will develop micrometastatic disease. Defining the expression of tumor-associated antigens on CaP will enable appropriate selection of therapeutic targets. METHODS AND MATERIALS: The expression of tumor-associated antigens on CaP cell lines (PC-3, DU 145, and LNCaP-LN3) was detected by immunohistochemistry and flow cytometry. Test and control alpha-conjugates were prepared using monoclonal antibodies, an inhibitor, plasminogen activator inhibitor type 2, that binds to the cell-membrane-bound protease, urokinase plasminogen activator, and a control protein labeled with (213)Bi using standard methods. These were used singly or together against three different CaP cell lines in vitro. The cytotoxicity of the alpha-conjugates was assessed using the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) assay. RESULTS: The PC-3 and DU 145 cancer cell lines expressed antigens that bind monoclonal antibodies BLCA-38 and #394 (mouse anti-human urokinase plasminogen activator B-chain) but not J591. The LNCaP-LN3 cells bound J591 but not #394 or BLCA-38. For the PC-3, DU 145, and LNCaP-LN3 cell lines, multiple-targeted alpha-therapy combining four alpha-conjugates (one-quarter doses of each) gave D(0) (37% cell survival) values of 15, 17, and 27 microCi/mL compared with those of the controls of 272, 289, and 281 microCi/mL, respectively. CONCLUSION: Metastatic prostate cancer-associated antigens recognized by multiple monoclonal antibodies are potential targets for alpha-therapy. Multiple-targeted alpha-therapy produced cytotoxicity specific to three CaP cell lines and may form the basis of treatment for micrometastatic CaP, overcoming the heterogeneity of expression of the targeted antigens.


Subject(s)
Antigens, Neoplasm/analysis , Bismuth/therapeutic use , Prostatic Neoplasms/immunology , Prostatic Neoplasms/radiotherapy , Radioimmunotherapy/methods , Radioisotopes/therapeutic use , Antibodies, Monoclonal/therapeutic use , Apoptosis , Cell Line, Tumor/immunology , Cell Proliferation/radiation effects , Humans , Immunoconjugates/therapeutic use , Male , Plasminogen Activator Inhibitor 2/therapeutic use , Prostatic Neoplasms/pathology
17.
Cancer Lett ; 205(2): 161-71, 2004 Mar 18.
Article in English | MEDLINE | ID: mdl-15036648

ABSTRACT

HER-2 has been implicated in the oncogenesis of human prostate cancer (CaP) and is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody (MAb) trastuzumab (Herceptin). In this study, a novel alpha-particle emitting [213Bi]Herceptin construct, which targets the HER-2 extracellular domain on CaP cells, was prepared and evaluated in vitro. We used immunocytochemistry, flow cytometry and Western blot analysis to examine the expression of HER-2 in a panel of established human CaP cell lines, used the MTS assay to evaluate the cytotoxicity of 213Bi-Herceptin on these cell lines and the TUNEL assay to document apoptosis. The results indicate that LNCaP-LN3 cells express high levels of HER-2 protein, in contrast, DU 145 cells express low to medium levels, and PC-3 cells express an undetectable level of HER-2 protein. 213Bi-Herceptin was specifically cytotoxic to LNCaP-LN3 cells in a concentration-dependent fashion, cause the cells to undergo apoptosis, whereas DU 145 showed an HER-2 level-dependent response to 213Bi-Herceptin cytotoxicity. In contrast, PC-3 cells were resistant to 213Bi-Herceptin-induced cytotoxicity. The 213Bi-Herceptin induced apoptosis in LNCaP-LN3 cells could be inhibited by incubation with unlabeled Herceptin. Our results suggest that 213Bi-Herceptin alpha-conjugate might be a promising new agent for the treatment of preangiogenic cancer cell clusters or micro-metastases with high levels of HER-2 expression.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Apoptosis/radiation effects , Bismuth/therapeutic use , Prostatic Neoplasms/radiotherapy , Radioimmunotherapy , Radioisotopes/therapeutic use , Antibodies, Monoclonal, Humanized , Cell Line, Tumor , Humans , Male , Prostatic Neoplasms/pathology , Receptor, ErbB-2/analysis , Trastuzumab
18.
ANZ J Surg ; 73(8): 649, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12887539

ABSTRACT

BACKGROUND: Identification of the true midline in infra-umbilical longitudinal incisions is often difficult. Traditional methods of identification can be unreliable. METHODS: An alternative technique for identifying the linea alba, based on the attachments of the median umbilical ligament, is presented. RESULTS: The technique is both reliable and reproducible in identifying the midline. CONCLUSION: This technique is recommended as a means of avoiding muscle incision and facilitating wound closure.


Subject(s)
Abdominal Wall/surgery , Surgical Procedures, Operative/methods , Abdominal Wall/anatomy & histology , Fascia/anatomy & histology , Fasciotomy , Humans
19.
Prostate ; 53(2): 95-100, 2002 Oct 01.
Article in English | MEDLINE | ID: mdl-12242723

ABSTRACT

BACKGROUND: Attenuated, replication-competent herpes simplex virus mutants offer an exciting new modality in cancer therapy through their ability to selectively replicate within and kill malignant cells with minimal harm to normal tissues. METHODS: This study investigates the efficacy of two such viruses, G207 and NV1020, in human prostatic carcinoma. In vitro studies were performed on four human prostatic carcinoma cell lines, and in vivo single/multiple dose studies were undertaken on mice by using two human cell types. Tumor volume, histopathology at necropsy, and serum prostate specific antigen (PSA) were used as measures of antiproliferative effect in the in vivo experiments. RESULTS: Both viruses were effective in producing cytolytic effects in vitro at various multiplicities of infection in all cell lines tested. Both viruses demonstrated antitumor effects in vivo with a statistically significant decrease in serum PSA and inhibition of growth of both PC-3 and C4-2 subcutaneous xenografts. Tumor-free animals at necropsy were observed in the treated groups but not in control animals. CONCLUSION: These results display impressive activity against human prostate cancer and offer promise for the use of this modality in the future.


Subject(s)
Carcinoma/therapy , Genetic Therapy/methods , Prostatic Neoplasms/therapy , Simplexvirus/genetics , Animals , Carcinoma/blood , Carcinoma/pathology , Cytopathogenic Effect, Viral , Humans , Male , Mice , Mice, Nude , Mutation/genetics , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology , Simplexvirus/physiology , Specific Pathogen-Free Organisms , Tumor Cells, Cultured , Virus Replication , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...